Covered recipient · General Payments record
LAURA L EBNER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Behavioral Neurology & Neuropsychiatry
General Payments · PY2023
$4,459.06
- Reported across 8 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $3,960.00 | 1 |
| Food and Beverage | $283.60 | 6 |
| Travel and Lodging | $215.46 | 1 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $4,459.06 | 8 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2023 | $4,459.06 | 8 |
Payment records · PY2023 (8)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $121.98 | 07/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1055381921 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $48.79 | 07/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1055381923 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.61 | 07/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1055381925 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.28 | 07/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1055381927 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $48.79 | 07/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1055381929 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.15 | 07/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1055381931 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $215.46 | 07/22/2023 | Travel and Lodging | Undisputed | 01/23/2026 | 1055381933 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,960.00 | 08/25/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1055381935 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023
- Source files
- Dataset page · Bulk file · PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.